CD5 and mantle cell lymphoma: These included mantle cell lymphoma (MCL) cases (3/26, 11.5%), CD5-negative B-cell lymphoproliferative disorder cases (4/26, 15.4%), and cases with unusual immunophenotypic features (2/26, 7.7%).